<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Globus Medical — News on 6ix</title>
<link>https://6ix.com/company/globus-medical</link>
<description>Latest news and press releases for Globus Medical on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Mar 2026 21:25:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/globus-medical" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835788578dffbe2df0f8155.webp</url>
<title>Globus Medical</title>
<link>https://6ix.com/company/globus-medical</link>
</image>
<item>
<title>Globus Medical Announces Board Departure</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-announces-board-departure</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-announces-board-departure</guid>
<pubDate>Mon, 23 Mar 2026 21:25:00 GMT</pubDate>
<description>AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the company of his decision to step down from the Board of Directors effective immediately and will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026. “We are grateful for John’s many contributions, especially during the merger with NuVasive and his service on</description>
</item>
<item>
<title>Globus Medical Reports Fourth Quarter and Full Year 2025 Results</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-reports-fourth-quarter-and-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-reports-fourth-quarter-and-full-year-2025-results</guid>
<pubDate>Tue, 24 Feb 2026 21:15:00 GMT</pubDate>
<description>AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currenc</description>
</item>
<item>
<title>Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-schedules-fourth-quarter-213000060</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-schedules-fourth-quarter-213000060</guid>
<pubDate>Thu, 12 Feb 2026 21:30:00 GMT</pubDate>
<description>AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment</description>
</item>
<item>
<title>Providence Medical Technology Appoints Industry Veteran Jim Hens as Chief Commercial Officer as the Company Continues Rapid Growth Following Publication of Landmark Study</title>
<link>https://6ix.com/company/globus-medical/news/providence-medical-technology-appoints-industry-veteran-jim-hens-as-chief-commercial-officer-as-the-company-continues-rapid-growth-following-publication-of-landmark-study</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/providence-medical-technology-appoints-industry-veteran-jim-hens-as-chief-commercial-officer-as-the-company-continues-rapid-growth-following-publication-of-landmark-study</guid>
<pubDate>Wed, 04 Feb 2026 11:00:00 GMT</pubDate>
<description>Providence Medical Technology (Providence), a pioneer in spinal fusion surgery technology, today announced the appointment of industry veteran Jim Hens as Chief Commercial Officer.</description>
</item>
<item>
<title>Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-reports-preliminary-record-212700644</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-reports-preliminary-record-212700644</guid>
<pubDate>Wed, 07 Jan 2026 21:27:00 GMT</pubDate>
<description>AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 per</description>
</item>
<item>
<title>Globus Medical Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-reports-third-quarter-211500790</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-reports-third-quarter-211500790</guid>
<pubDate>Thu, 06 Nov 2025 21:15:00 GMT</pubDate>
<description>AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0</description>
</item>
<item>
<title>Globus Medical Schedules Third Quarter Earnings Release and Conference Call</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-schedules-third-quarter-203000501</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-schedules-third-quarter-203000501</guid>
<pubDate>Thu, 16 Oct 2025 20:30:00 GMT</pubDate>
<description>AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after the market close on Thursday, November 6, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at</description>
</item>
<item>
<title>Globus Medical Launches ANTHEM™ Elbow Fracture System: A Comprehensive Plating Portfolio for Complex Elbow Trauma</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-launches-anthem-elbow-204000186</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-launches-anthem-elbow-204000186</guid>
<pubDate>Tue, 14 Oct 2025 20:40:00 GMT</pubDate>
<description>AUDUBON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System, a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures. The ANTHEM™ Elbow Fracture System is designed to offer surgeons anatomically contoured plates to treat a variety of fractures, regardless of severity or complexity, with a simplified workflow. Engineered to simpli</description>
</item>
<item>
<title>Globus Medical, Inc. Secures Jury Verdict in Delaware Patent Litigation Against Life Spine, Inc.</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-inc-secures-jury-203000024</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-inc-secures-jury-203000024</guid>
<pubDate>Thu, 28 Aug 2025 20:30:00 GMT</pubDate>
<description>AUDUBON, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, announced that a Delaware jury has returned a verdict in favor of Globus in its patent infringement litigation against Life Spine, Inc. The jury found that Life Spine’s Prolift family of implants infringed several claims of a valid Globus patent and awarded Globus both lost profits and reasonable royalty damages. The technology at issue involves expandable spinal fusio</description>
</item>
<item>
<title>Globus Medical Reports Second Quarter 2025 Results</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-reports-second-quarter-201500928</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-reports-second-quarter-201500928</guid>
<pubDate>Thu, 07 Aug 2025 20:15:00 GMT</pubDate>
<description>AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net sales were $745.3 million, an increase of 18.4%, or an increase of 17.6% on a constant currency basisGAAP net income for the quarter was $202.8 millionGAAP diluted earnings per share (“EPS”) was $1.49 and non-GAAP diluted EPS was $0.86 “Q2 results were led by our US Spine business,</description>
</item>
<item>
<title>Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-announces-leadership-transitions-120000850</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-announces-leadership-transitions-120000850</guid>
<pubDate>Mon, 21 Jul 2025 12:00:00 GMT</pubDate>
<description>AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer effective July 18, 2025, in order to pursue another opportunity. Additionally, Kyle Kline, Senior Vice Pre</description>
</item>
<item>
<title>Globus Medical Schedules Second Quarter Earnings Release and Conference Call</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-schedules-second-quarter-203000150</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-schedules-second-quarter-203000150</guid>
<pubDate>Thu, 17 Jul 2025 20:30:00 GMT</pubDate>
<description>AUDUBON, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2025 after the market close on Thursday, August 7, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30</description>
</item>
<item>
<title>Globus Medical Introduces DuraPro™ with Navigation, a Next-Generation, Oscillating System Designed to Safeguard Delicate Tissue</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-introduces-durapro-navigation-201500274</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-introduces-durapro-navigation-201500274</guid>
<pubDate>Tue, 15 Jul 2025 20:15:00 GMT</pubDate>
<description>AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency. “Our goal is to revolutionize the $550 million high-speed drill market with the introduction of innovative, next generation osc</description>
</item>
<item>
<title>Globus Medical Announces $500 Million Share Repurchase Program</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-announces-500-million-203000857</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-announces-500-million-203000857</guid>
<pubDate>Thu, 15 May 2025 20:30:00 GMT</pubDate>
<description>AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company’s outstanding common stock. “We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation,” said Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globu</description>
</item>
<item>
<title>Globus Medical Reports First Quarter 2025 Results</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-reports-first-quarter-201500979</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-reports-first-quarter-201500979</guid>
<pubDate>Thu, 08 May 2025 20:15:00 GMT</pubDate>
<description>AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share (“EPS”) was $0.54 and non-GAAP diluted EPS was $0.68 “Our first quarter results were impacted by softer E</description>
</item>
<item>
<title>Globus Medical Schedules First Quarter Earnings Release and Conference Call</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-schedules-first-quarter-203000654</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-schedules-first-quarter-203000654</guid>
<pubDate>Thu, 17 Apr 2025 20:30:00 GMT</pubDate>
<description>AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com. Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.</description>
</item>
<item>
<title>Globus Medical completes acquisition of Nevro Corp.</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-completes-acquisition-nevro-123100203</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-completes-acquisition-nevro-123100203</guid>
<pubDate>Thu, 03 Apr 2025 12:31:00 GMT</pubDate>
<description>AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. “We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and bringing a much-needed treatme</description>
</item>
<item>
<title>Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-extends-versatility-advanced-204000021</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-extends-versatility-advanced-204000021</guid>
<pubDate>Tue, 11 Mar 2025 20:40:00 GMT</pubDate>
<description>AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, andModulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system. The COHERE ™ ALIF Spacer is the latest addition to Globus Medical’s Advanced Materials Science™ (AMS) implant portfo</description>
</item>
<item>
<title>Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-feature-excelsiusflex-total-214000154</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-feature-excelsiusflex-total-214000154</guid>
<pubDate>Thu, 06 Mar 2025 21:40:00 GMT</pubDate>
<description>AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025. Join Globus at booth #2517 to learn about the comprehensive Globus Medical product portfolio across Spine, Trauma, and Joint Reconstruction procedures; Enabling Technology; Power Tools; and Regenerative Biom</description>
</item>
<item>
<title>Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference</title>
<link>https://6ix.com/company/globus-medical/news/globus-medical-participate-canaccord-genuity-000100653</link>
<guid isPermaLink="true">https://6ix.com/company/globus-medical/news/globus-medical-participate-canaccord-genuity-000100653</guid>
<pubDate>Thu, 06 Mar 2025 00:01:00 GMT</pubDate>
<description>Monday, March 10, 2025 at 4:30 pm Pacific TimeAUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 4:30 pm PT. Interested parties can access the live and archived webcast of the presentation in the “News & Events”, “Events & Webcasts” sectio</description>
</item>
</channel>
</rss>